Publications

AKB-9778 Publications and Presentations

Aerpio -I-SPY COVID Summary Presentation

May 2020

A Novel Approach to Glaucoma  Treatment Targeting Tie2 in the  Conventional  Outflow Pathway

Presented at: Glaucoma 360 New Horizons in Pharmaceuticals, (2020)

Enhanced Benefit in Diabetic Macular Edema from AKB-9778 Tie2 Activation Combined with Vascular Endothelial Growth Factor Suppression

Published in Ophthalmology (2016)

Presented at the Glaucoma 360 meeting in San Francisco CA 07 Feb 2020

Published in Current Diabetes Report (2016)

Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema

Published in Pharmaceuticals (2020)

Angiopoietin-2-induced blood-brain barrier compromise and increased stroke size are rescued by VE-PTP-dependent restoration of Tie2 signaling

Published in Acta Neuropathologica (2016)

Treatment of Diabetic Macular Edema with an Inhibitor of Vascular Endothelial-Protein Tyrosine Phosphatase That Activates Tie2

Published in Ophthalmology (2015)

Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin

Published in The Journal of Experimental Medicine (2015)

Targeting VE-PTP activates Tie2 and stabilizes the ocular vasculature

Published in The Journal of Clinical Investigation (2014)

Effects of vascular-endothelial protein tyrosine phosphatase inhibition on breast cancer vasculature and metastatic progression

Published in The Journal of the National Cancer Institute (2013)

Inhibiting the Inhibitor: Targeting Vascular Endothelial Protein Tyrosine Phosphatase to Promote Tumor Vascular Maturation 

Published in The Journal of the National Cancer Institute (2013)

ARP-1536 Publications

Interfering with VE-PTP stabilizes endothelial junctions in vivo via Tie-2 in the absence of VE-cadherin

Published in The Journal of Experimental Medicine (2015)

Targeting VE-PTP activates Tie2 and stabilizes the ocular vasculature

Published in The Journal of Clinical Investigation (2014)

AKB-4924 Publications

Regulation of IL-12p40 by HIF controls Th1/Th17 responses to prevent mucosal inflammation

Published in Mucosal Immunology (2017)

Inhibition of HIF Prolyl Hydroxylases Mitigate Gut Graft-Versus-Host Disease

Presented at American Society of Hematology Annual Meeting (2016)

Oral delivery of prolyl hydroxylase inhibitor: AKB-4924 promotes localized mucosal healing in a mouse model of colitis.

Published in Inflammatory Bowel Disease (2015)

Contribution of epithelial innate immunity to systemic protection afforded by prolyl hydroxylase inhibition in murine colitis.

Published in Mucosal Immunology (2014)

Transmigrating Neutrophils Shape the Mucosal Microenvironment through Localized Oxygen Depletion to Influence Resolution of Inflammation

Published in Immunity (2014)

A New Pharmacological Agent (AKB-4924) Stabilizes Hypoxia Inducible Factor (HIF) and Increases Skin Innate Defenses Against Bacterial Infection

Published in Journal of Molecular Medicine (2012)